Updated DHHS guidelines emphasize shared decision making between the pregnant person living with or at risk for HIV and their care provider.
Sponsoring Organization: Department of Health and Human ServicesTarget Audience: Infectious disease specialists, obstetricians and gynecologists, neonatologists, and pediatricians
Background and Objective
An expert panel has issued updated recommendations about treatment for pregnant people living with HIV and prevention of perinatal transmission.
What's New
Although data are limited regarding safety and efficacy of long-acting cabotegravir (CAB-LA) for preexposure prophylaxis (PrEP) in pregnant persons, anticipated benefits may outweigh risks in some settings. The patient and their provider should engage in shared decision making if the patient wishes to initiate PrEP while pregnant (or if becoming pregnant while on CAB-LA). If seroconversion …
Reviewing Author
DisclosuresConsultant/Advisory BoardNIH Therapeutics and Prevention Data Safety Monitoring Board
Leadership Positions in Professional SocietiesAmerican Board of Internal Medicine Infectious Diseases Subspecialty Board (member), Infectious Diseases Society of America (Vice President)
DisclosuresConsultant/Advisory BoardNIH Therapeutics and Prevention Data Safety Monitoring Board
Leadership Positions in Professional SocietiesAmerican Board of Internal Medicine Infectious Diseases Subspecialty Board (member), Infectious Diseases Society of America (Vice President)